XML 78 R67.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Information - Schedule of Revenue by Different Product Lines (Details) - USD ($) | 3 Months Ended
--- | ---
Mar. 31, 2018 | Mar. 31, 2017
Product Revenue Total | $ 302,475 | $ 667,250
License Fees |  |
Total Revenue | 302,475 | 667,250
MicroParticle Catalyzed Biosensor ("MPC") [Member] |  |
Product Revenue Total | 18,950 | 85,659
Particle ImmunoFiltration Assay ("PIFA") [Member] |  |
Product Revenue Total | 259,983 | 560,921
Rapid Enzymatic Assay ("REA") [Member] |  |
Product Revenue Total | 9,900 |
Other [Member] |  |
Product Revenue Total | $ 13,642 | $ 20,670

X
- Definition License Fees. + References No definition available. + Details
Name: | AKER_LicenseFees
Namespace Prefix: | AKER_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from contract with customers. + References No definition available. + Details
Name: | AKER_RevenueFromContractWithCustomers
Namespace Prefix: | AKER_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=AKER_MicroParticleCatalyzedBiosensorMPCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AKER_ParticleImmunoFiltrationAssayPIFAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AKER_RapidEnzymaticAssayREAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AKER_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |